Renaissance Capital logo

Metacrine Priced, Nasdaq: MTCR

Phase 1 biotech developing FXR agonist therapies for NASH.

Industry: Health Care

Latest Trade: $9.90 0.00 (0.0%)

First Day Return: -9.5%

Return from IPO: -23.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal, or GI, diseases. Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis, or NASH, a liver disease characterized by excess liver fat, inflammation and fibrosis. We believe that potency, sustained exposure and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds, and have selected two novel, oral FXR candidates from a unique chemical scaffold, MET409 and MET642, that have the potential to deliver improved tolerability and therapeutic outcomes. MET409 and MET642 were purposefully designed to be differentiated treatments for NASH as potent, sustained FXR agonists with the ability to be dosed orally once daily. With our program, we believe we can develop differentiated FXR agonist therapies for NASH and other GI diseases.
more less
IPO News for Metacrine
more
IPO Data
IPO File Date 08/24/2020
Offer Price $13.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.5
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/15/2020
Offer Price $13.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.5
Deal Size ($mm) $85
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2014
Employees 32
Website www.metacrine.com